DermTech, Inc.

Constellation Alpha Capital Corp. (Nasdaq: CNAC) was a blank-check company sponsored by Constellation Alpha Capital Corp.'s management team that completed its initial public offering in 2017, targeting the healthcare and life sciences sector. The SPAC announced a business combination with DermTech, Inc., a La Jolla-based precision dermatology company known for its non-invasive genomic testing technology for skin conditions including melanoma detection. The August 2019 Form 8-K filing with the SEC, carrying accession number 0001193125-19-232486, was submitted in connection with the progression of that combination. Following the transaction's close, the combined company operated as DermTech in the precision medicine and diagnostics space. Sign up for a full SpacDesk account to access complete filing histories, sponsor profiles, and deal analytics on CNAC and hundreds of other SPAC transactions.